tiprankstipranks
pc:illim

Illimis Therapeutics

18, Heolleung-ro 569-gil, Gangnam-gu Seoul, 06376, KR
https://www.illimistx.com/
Illimis Therapeutics is a biotechnology company focused on developing innovative treatments for challenging cancers, Alzheimer's, and immune diseases. Leveraging its proprietary GAIA platform, the company aims to advance its drug development pipeline through strategic global partnerships, including collaborations with industry leaders like Lilly Catalyze360-ExploR&D.

Leadership & Board

Current Number of Employees24
Current LinkedIn Followers556

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$42M
Total Amount Raised$42M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$42M
Latest Funding Amount$42M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

Illimis Therapeutics had 24 employees as of April 6, 2026. The number of employees increased by 0 (0.00%) week-over-week.
24Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Illimis Therapeutics had 556 followers as of April 6, 2026. The number of followers increased by 0 (0.00%) week-over-week.
556Latest Followers Count
0(0.00%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jul 14, 2025
Series B
$42.00M

Investors

Related News and Analysis